Jbi-802 free base
As of the edition of 20 October 2026, Jbi-802 free base is a small molecule: in active development; acts on HDAC6 and KDM1A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Active, 2026
- Kind
- Small molecule
- Registered trials
- 3, 0 stopped early
- Disease areas
- Cancer; Blood and lymph; Lungs and airways
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 2 | 3 | 0 | 2 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Jubilant Therapeutics | Lead sponsor of trials | 2022 to now |